Neoadjuvant Therapy for High-Risk Prostate Cancer

Adam S. Kibel, MD, argues that, while it is common to debate the best intervention method for local prostate cancer, there also must be an emphasis on the systemic treatment of micro-metastatic disease in the interest of decreasing disease-specific death. He then reviews the impact of timing, duration, and intensity of systemic therapy on patient outcomes, focusing on four trials evaluating neoadjuvant therapy for high-risk prostate cancer.

• #education
• #adam_s_kibel
• #micro_metastatic_prostate_cancer
• #systemic_therapies_for_prostate_cancer
• #neoadjuvant_therapy_for_high_risk_prostate_cancer
• #adt_for_prostate_cancer
• #androgen_deprivation_therapy
• #mcrpc
• #high_risk_prostate_cancer
• #grand_rounds_in_urology